The search for safe and effective drugs to treat schizophrenia is hindered by the complex nature of this disorder, which is known to involve multiple brain neurotransmitters.
Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant.
In this regard, cannabidiol (CBD), a non-psychoactive constituent of Cannabis/Hemp, has shown significant promise as a potential antipsychotic for the treatment of schizophrenia.
CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile.
Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.
Preclinical and clinical studies since the 90s have demonstrated the antipsychotic potential of cannabidiol (CBD), a derivative of the Cannabis/Hemp plant which does not have the adverse psychoactive properties of tetrahydrocannabinol.
In particular, CBD has been shown to be effective in attenuating the positive symptoms of schizophrenia with a negligible side-effect profile. However, the underlying antipsychotic mechanism of antipsychotic action of CBD remains unclear.
Cannabidiol is a component of Cannabis/Hemp that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. An elevation of anandamide levels in cerebrospinal fluid inversely correlates to psychotic symptoms.
CBD displays a markedly superior side-effect profile than dangerous pharmaceutical drugs. Moreover, cannabidiol treatment is accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement.
The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
However, there is still considerable uncertainty about the mechanism of action of CBD as well as the brain regions which are thought to mediate its putative antipsychotic effects. We argue that further research on CBD is required to fast-track its progress to the clinic and in doing so, we may generate novel insights into the neurobiology of schizophrenia.
In saying all that there is also plenty of anecdotal evidence of people using this natural plant based anti-psychotic to treat their condition safely and effectively. If you believe this treatment is right for you then by all means we invite you to try one of our product offerings on this website, our homepage has the highest potency CBD capsules on the market up for grabs, and our cannabidiol crystals page has not only high dose cannabidiol crystals for sale, but also CBD vapour oils, and CBD tinctures. May health be on your side!